PIK3CA-related Overgrowth Spectrum (PROS) research hub
4 indexed studies · 2 currently recruiting
- recruitingPHASE2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
This study looks at how well a medicine called alpelisib works for children and adults with a condition called PROS, which causes parts of the body to grow too much. It also checks if the medicine is safe and how it moves through the body.
United States · Australia · Austria - active not recruitingPHASE2
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
This study looks at how safe and effective Alpelisib is for children and adults with PROS (a growth condition) over a long time. It includes people who were in a previous study and explores if the medication helps them.
United States · France · Ireland - recruitingPHASE2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
This study is testing a new medicine called RLY-2608 for adults and children with certain conditions where parts of their body have grown too much or developed unusually due to a specific genetic change. It aims to see if the medicine is safe and if it can help improve these conditions.
United States · Australia · Belgium - active not recruitingPHASE2
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
This study is testing a new medicine, Alpelisib, for children and adults with a condition called PIK3CA-related overgrowth spectrum (PROS). Researchers want to see if it's safe and effective in helping manage the overgrowth caused by this condition.
United States · Canada · China